{
  "docId": "019de073-c7d4-73ef-8fef-22f9b5017668",
  "docSlug": "c95aa30aee69a466f8f903e1480a3b33",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 32 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 32,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The slide uses a process flow diagram to show the relationship between SAD and MAD trials.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-c7d4-73ef-8fef-22f9b5017668/9",
  "deckHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668",
  "deckJsonHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668.json",
  "deckAnchorHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.04,
        "y": 0.4
      },
      "kind": "diagram",
      "text": "SAD to MAD transition flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "585cc262-06d3-4ea2-8a34-1806d3f88d1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.8,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Two double-blind, placebo-controlled dosing trials in patients with FA; Patient dosing began December 2019; Safety Review Committee assessed all blinded data between each cohort to ensure patient safety",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5f456f25-7680-4038-a248-3228eab9d88d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.8,
        "x": 0.04,
        "y": 0.12
      },
      "kind": "paragraph",
      "text": "Program consisted of double-blind, placebo controlled single- and multiple-ascending dose trials. Phase 1 Development Plan.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "77492a97-8440-4ec0-a919-d1539e178dcb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.35,
        "y": 0.4
      },
      "kind": "table",
      "text": "SAD trial details: 28 subjects, 25-100mg doses, 1 day duration, safety/tolerability primary endpoint, complete status.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6fa97b22-4a48-4632-b371-6daa9ac54717",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "table",
      "text": "MAD trial details: 27 subjects, 25-100mg doses, 13 days duration, safety/tolerability primary endpoint, complete status.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2f2234c-53a1-42b8-a3b6-a286818793e0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "CTI-1601: Phase 1 Clinical Program in Patients with FA",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b3b010a-aedd-4535-9a3b-91dfed7df7f7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "ff8f8107-de0e-468b-af72-72f25cc739ca",
      "evidence": "Flow diagram showing progression from SAD to MAD trials",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 13,
      "from": 8,
      "beatId": "8bf4cfad-4916-4c9e-af27-192a9a042ffa",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck highlights positive clinical trial results",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 13,
      "from": 8,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "d0d0eba8-b767-4a62-beb5-07c937ed50af",
      "evidence": "The deck presents positive clinical trial results",
      "position": 2,
      "objective": "Demonstrate the efficacy of CTI-1601",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.8,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}